Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Common Equity (2024 - 2025)

Historic Common Equity for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $242.5 million.

  • Kura Oncology's Common Equity fell 4276.58% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year decrease of 4276.58%. This contributed to the annual value of $413.6 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's Common Equity is $242.5 million, which was down 4276.58% from $305.5 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Common Equity peaked at $505.1 million during Q1 2024, and registered a low of $242.5 million during Q3 2025.